Skip to main content
. 2016 Sep 20;7(43):70080–70091. doi: 10.18632/oncotarget.12148

Figure 1. FRMD6 is down-regulated in human glioblastoma cells and tissues.

Figure 1

(A) Levels of endogenous FRMD6 protein in a panel of human GBM cells and normal human astrocytes (NHAs, ScienCell Research Laboratories) were determined by Western blotting using anti-FRMD6 antibody (Sigma, upper panels). 50 μg of proteins were loaded into each lane. Actin was included as an internal control for loading (bottom panels). (B) Immunohistochemistry (IHC) analyses were performed on 10 human GBM samples and 10 normal human brain samples using anti-FRMD6 antibody (Sigma). Representative pictures of the antibody staining patterns of FRMD6 in normal brain (upper two panels) and GBM tissues (bottom two panels) are shown. Bar, 150 μm. (C) Scoring of the IHC results: Intensity of immunoreactivity to anti-FRMD6 antibody in 10 GBM and 10 normal brain cases were scored as the following: score 0 = negative, 1 = weak, 2 = intermediate, and 3 = strong staining. The scores were averaged and standard deviations and p values were calculated. **p < 0.01.